Reinventing the end-to-end model
Syneos One® is a fully integrated, insights-driven, end-to-end asset development offering that leverages a single point of contact for our customers across the asset lifecycle. A small biotech customer partnered with Syneos One to bring its life-changing asset to market. Our team navigated Phase II trials with them and we are now on the doorstep of bringing this important drug to market in early 2022.